SAN DIEGO--(BUSINESS WIRE)-- Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced the appointment of Kelly Choi, MD, as Senior Vice President, Marketing and Product Management. Dr. Choi brings 20 years of commercial leadership experience in product strategy and execution, strategic partnerships, business development, client relations, and operations management for healthcare technology companies.

“With her impressive background, Dr. Choi will amplify our commercialization efforts and market our newly launched AVITI System to ensure that we successfully deliver on our promise of empowering the scientific community with more freedom to study biology,” said Molly He, PhD, CEO and co-founder of Element Biosciences. “We continue to assemble an outstanding executive leadership team at Element so that we can make genetic analysis more accessible and adaptable to a broad customer base.”

In her new role, Dr. Choi will build, guide and manage product strategy, strategic marketing, field marketing and product management. She will work closely with the leadership team and Board to develop external partnerships and implement strategies for appropriately positioning and driving adoption of current and future products in the marketplace.

Prior to joining Element, Dr. Choi was Chief Commercial Officer at Onegevity, a start-up within the science-driven wellness company, Thorne HealthTech, where she was responsible for building and growing their B2B business and scientific partnerships. She gained significant experience in the precision oncology space working with cancer providers, researchers and life science companies during her time at Tempus Labs, GenomOncology and COTA (Cancer Outcomes Tracking Analysis). Earlier experiences include brand marketing at Novartis and management consulting at McKinsey & Company.

Dr. Choi completed her fellowship in cardiology at Duke University School of Medicine in North Carolina after finishing her residency in Internal Medicine at Northwestern Medical Center and medical school at the Feinberg School of Medicine at Northwestern University in Chicago.

“I am excited to join Element and support the efforts of both the commercial and R&D teams to democratize access to genomics by developing the right technologies into critical products,” said Dr. Choi. “With the AVITI System, customers in the research and clinical markets now have the tools they need to accelerate scientific discoveries and broaden the use of genomic medicine overall.”

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. Learn more at elementbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005150/en/